Navigation Links
Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
Date:3/6/2008

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2007, after the close of market on March 13, 2008. The company's earnings conference call will take place March 13, 2008, at 2 p.m. PDT (5 p.m. EDT).

Third-Quarter Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, March 13, 2008

Participants are invited to call 877-545-1491 or 719-325-4931. The live event will be available on Trubion's Web site at http://investors.trubion.com/events.cfm.

A replay of the discussion can be obtained beginning at 8 p.m. EDT March 13 by visiting Trubion's Web site or calling 888-203-1112 or 719-457-0820 and entering the code 7634379. The telephone replay will be available until midnight on Monday, March 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.

Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

TRBN-G

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals, Inc.

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Jenny Moede

Senior Vice President

503-443-7000

jmoede@wagged.com


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Trubion Announces Presentations at Upcoming Investor Conferences
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... San Antonio, TX (PRWEB) , ... May 22, 2017 , ... ... It starts with a body squatted, stretched, jumped, toned and shaped through fitness programs. ... And it is, of course, finished off with an irresistible, radiant smile. CDA ...
(Date:5/21/2017)... Texas (PRWEB) , ... May 19, 2017 , ... ... is pleased to announce the appointment of James (Jim) Vertino as Chief Information ... is a proven, transformational leader who drives innovation and business performance. He defines ...
(Date:5/21/2017)... ... May 21, 2017 , ... For the past ... group of scholars, policymakers, and activists wanting to address equity issues in breastfeeding, ... the third book from a recent series of from this conference. , ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... been longer than six months since you've seen a dentist, it's time for ... year and getting x-rays once per year. , Dental checkups are a relatively ...
(Date:5/19/2017)... , ... May 19, 2017 , ... When Kyle Busch ... his name will already appear on two major research studies that could impact the ... with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017 Clarius Mobile Health, a digital ... scanners this week at the American Congress of ... San Diego, CA from ... the perfect tool for clinicians to easily confirm ... evaluate pregnancy-related complications like ectopic pregnancy and placenta ...
(Date:5/4/2017)... May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is teaming ... STI Technologies Limited to lower diabetes healthcare costs in ... innoviCares card, which is available throughout all provinces and ... will be eligible for additional savings when shopping for ...
(Date:5/4/2017)... BOTHELL, Wash. , May 4, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... media ("BioLife" or the "Company"), today announced that ... released after market close on Thursday, May 11, 2017, ... and live webcast at 1:30 p.m. PT that afternoon. ...
Breaking Medicine Technology: